Clinical trials: Advanced Solid Tumors (Phase 1)
Solid Tumors
Dose Escalation Study of NKP-1339 to Treat Advanced Solid Tumors
The purpose of this study is to determine the safety and maximal tolerated dose of NKP-1339, a ruthenium containing compound administered intravenously on a weekly schedule, in patients with advanced solid tumors.
- Trial name
- NCT01415297
- Testing
- NKP-1339
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- Niiki Pharma Inc.
ER+ HER2- Advanced Breast Cancer, High-grade Serous Ovarian Cancer (HGSOC)
A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors
This study is designed to evaluate AZD8421 alone and in combination with selected targeted anti-cancer drugs in patients with ER+HER2- advanced breast cancer, and patients with metastatic high-grade serious ovarian cancer.
- Trial name
- CYCAD-1 (NCT06188520)
- Testing
- AZD8421, Camizestrant, Ribociclib
- Where
- 13 sites in United States, Australia and 3 more
- Volunteers
- 55 people
- Sponsor
- AstraZeneca
Advanced Solid Tumor
A Study of KL590586 in Patients With Advanced Solid Tumors
An Open, Multi-Center Phase I/II Clinical Study To Evaluate The Safety, Tolerability, Pharmacokinetic Characteristics And Effectiveness Of KL590586 Capsules In Patients With Advanced Solid Tumors Carrying RET Fusion Or Mutant…
- Trial name
- NCT05265091
- Testing
- KL590586 Capsule
- Where
- China
- Volunteers
- 414 people
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Advanced Solid Tumor
A First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors
This is a first-in-human, Phase 1a/1b study to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of BGB-C354 alone and in combination with tislelizumab in participants with advanced solid…
- Trial name
- NCT06422520
- Testing
- BGB-C354, Tislelizumab
- Where
- 14 sites in United States, Australia and 1 more
- Volunteers
- 63 people
- Sponsor
- BeOne Medicines
Advanced Solid Tumors
A Study of Sirolimus for Injection (Albumin Bound) in Patients With Advanced Solid Tumors
The purpose of this study is to estimate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of Sirolimus for Injection (Albumin Bound) in patients with solid malignancies.
- Trial name
- NCT05125523
- Testing
- Sirolimus for Injection (Albumin Bound)
- Where
- China
- Volunteers
- 264 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Solid Tumor, Adult
Isunakinra Alone and in Combination With a PD-1/PD-L1 Inhibitor in Patients With Solid Tumors
Isunakinra - a potent Interleukin-1 receptor inhibitor - will be given to patients with solid tumors to determine safety and tolerability of three different doses. Isunakinra will then be combined with a PD-(L)1 inhibitor.
- Trial name
- NCT04121442
- Testing
- Isunakinra, PD-(L)1 Inhibitor
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Buzzard Pharmaceuticals
Advanced Solid Tumors
An Investigation of TAS-119 Monotherapy
A Phase 1, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of TAS-119 in Patients with Advanced Solid Tumors.
- Trial name
- NCT02448589
- Testing
- TAS-119
- Where
- 6 sites in United States, Italy and 3 more
- Volunteers
- 74 people
- Sponsor
- Taiho Oncology, Inc.
Solid Tumor, Non-Small Cell Lung Cancer
Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
This is a multi-center, open-label, Phase I/II clinical study of MCLA-129 as monotherapy in patients with advanced solid tumors to evaluate the safety, pharmacokinetic characteristics and antitumor activity of MCLA-129.
- Conditions
- Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Colorectal Cancer
- Trial name
- NCT04930432
- Testing
- MCLA-129
- Where
- 87 sites in China
- Volunteers
- 400 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Advanced Solid Tumors, Advanced Recurrent Ovarian Tumors
A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors
To determine the maximum tolerated dose or optimal biological dose, and the safety profile of MEDI3617 when given as a single-agent or in combination with other chemotherapeutic agents in subjects with advanced solid malignancies…
- Trial name
- NCT01248949
- Testing
- MEDI3617, Bevacizumab, Paclitaxel
- Where
- 10 sites in United States
- Volunteers
- 162 people
- Sponsor
- MedImmune LLC
Neoplasms, Cancer
Bioavailability and Food Effect Study of TKI258 (CSF Capsules vs. FMI Capsules)in Adult Patients With Advanced Solid Tumors
This study will evaluate the relative bioavailability of 2 oral formulations of TKI258, and the effect of food on the bioavailability of TKI258, in adult patients with advanced solid tumor
- Conditions
- Neoplasms, Cancer, Tumors
- Trial name
- NCT01030055
- Testing
- TKI258 (dovitinib)
- Where
- 4 sites in United States
- Volunteers
- 60 people
- Sponsor
- Novartis Pharmaceuticals
Solid Tumors
Liposome Encapsulated Docetaxel (LE-DT) in Patients With Solid Tumors
Liposome Encapsulated Docetaxel (LE-DT) is a novel proprietary delivery system of docetaxel developed by NeoPharm, Inc. In this Phase I study, the LE-DT was evaluated for the maximum tolerated dose and dose limiting toxicity…
- Trial name
- LE-DT (NCT01151384)
- Testing
- LE-DT
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- INSYS Therapeutics Inc
Advanced Solid Malignancies, Malignant Lymphoma
Global Phase1 Study to Assess the Safety and Tolerability of AZD1208 in Advanced Solid Tumors and Malignant Lymphoma
The purpose of this study is to investigate the safety and tolerability of AZD 1208 up to a maximum tolerated dose (MTD) and define the dose(s) for further clinical evaluation when given daily to patients with advanced solid…
- Trial name
- NCT01588548
- Testing
- AZD1208
- Where
- 3 sites in Japan, United Kingdom
- Volunteers
- 43 people
- Sponsor
- AstraZeneca
Melanoma, Non Small Cell Lung Cancer
Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors
AI-061 is a co-formulation drug product (DP) consisting of 1:1 ratio mix of AI-025, an anti-PD-1 antibody, and ONC-392, an anti-CTLA-4 antibody.
- Conditions
- Melanoma, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, High Grade Serous Adenocarcinoma of Ovary
- Trial name
- PRESERVE-009 (NCT05858736)
- Testing
- AI-061
- Where
- 5 sites in Australia
- Volunteers
- 18 people
- Sponsor
- OncoC4, Inc.
Advanced Solid Tumors
Phase I Open-Label Study of P1101 Followed by P1801 in Advanced Solid Tumors
The goal of this clinical trial is to learn the safety of sequential treatment with P1101 and P1801 in advanced solid tumors. It will also learn the maximum tolerated dose (MTD) of P1801.
- Trial name
- NCT07053904
- Testing
- Sequential use of P1101 and P1801
- Where
- 2 sites in Taiwan
- Volunteers
- 54 people
- Sponsor
- PharmaEssentia
Solid Tumor
Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody
The purpose of this study is to assess the safety and tolerability of Hu5F9-G4 in participants with solid tumors.
- Trial name
- NCT02216409
- Testing
- Hu5F9-G4
- Where
- 6 sites in United States
- Volunteers
- 88 people
- Sponsor
- Gilead Sciences
Cancer
A Trial of PDL192 in Subjects With Advanced Solid Tumors
This is a phase 1, multicenter, open-label, dose escalation trial of PDL192 in subjects with advanced solid tumors.
- Trial name
- NCT00738764
- Testing
- PDL192
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Abbott
Locally Advanced Solid Tumor
Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors
This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion…
- Trial name
- NCT05275478
- Testing
- TNG908
- Where
- 20 sites in United States, France
- Volunteers
- 110 people
- Sponsor
- Tango Therapeutics, Inc.
Advanced Solid Tumors
A Phase I Study of NTQ1062 in Chinese Patients With Advanced Solid Tumors
This is an open-label, single-arm, phase 1 study to evaluate the safety, tolerability, pharmacokinetics, and preliminary pharmacodynamic effect of NTQ1062 in patients with advanced solid tumors.
- Trial name
- NCT06172309
- Testing
- NTQ1062
- Where
- 2 sites in China
- Volunteers
- 32 people
- Sponsor
- Nanjing Chia-tai Tianqing Pharmaceutical
Solid Tumor, Adult
A Study of BH009 in Head and Neck Squamous Cell Carcinoma and Ovarian Cancer
This study will assess the safety and tolerability and pharmacokinetics of BH009 in patients with advanced head and neck squamous (non-nasopharyngeal) and ovarian cancer.
- Trial name
- NCT06232863
- Testing
- BH009
- Where
- 5 sites in China
- Volunteers
- 24 people
- Sponsor
- Zhuhai Beihai Biotech Co., Ltd
Cancer
Safety Study of PRLX 93936 in Patients With Advanced Solid Tumors
The purpose of this study is to test the safety of PRLX 93936 and see what kind of effect it has on patients and their cancer. This study will also determine the highest dose of PRLX 93936 that can be given without causing…
- Trial name
- NCT00528047
- Testing
- PRLX 93936
- Where
- 3 sites in United States
- Volunteers
- 37 people
- Sponsor
- Prolexys Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.